

1

. * . **
. * . **

=Abstract=

A Case of Hepatic Metastasis in Granulosa Cell Tumor of the Ovary

S.G. Park, M.D., Y.S. Shin, M.D., S.K. Son, M.D., S.L. Nam, M.D.,
K.S. Seo, M.D.,* S.Y. Kim, M.D.**

Department of Obstetrics and Gynecology, Department of Pathology,
Department of Internal Medicine,** College of Medicine, Chungnam National University, Daejeon, Korea*

Granulosa cell tumor of the ovary accounts for 2-3% of all ovarian malignancies and is the most common sex-cord tumor. It has a relatively low malignant potential and a propensity for late recurrences, and so is associated with long-term survival. The incidence of hepatic metastasis has not been reported frequently, but appears to be low. We present a case of early hepatic metastasis of granulosa cell tumor of the ovary with a brief review of literatures.

Keywords: Granulosa cell tumor, Hepatic metastasis

: , 56
: 5-0-2-5
: 1979
가 , 1994 6
가 . 1995 12 1 5
10% .1 가 1
estrogen
가 estrogen
6.9 g/dl
가 가 , , ,
5 6% .2
가
(Fig. 1).
22 × 14
9 1 × 5 cm
가 가

가
가 a
가
(Fig. 3).

Fig. 1. 12×11×12 cm sized, multilobulated and multi-septated mixed mass located in the pelvic cavity and posterior and superior aspects of urinary bladder (pelvic CT).

1.5×1.1 cm 가 80 cc 가
3 4/10 HPF Call-Exner
body (Fig. 2).

Fig. 3. Fistulous tract of small intestine showing focal invasion of tumor cell nests and granulation tissue proliferation (H & E, ×40).

가 :
: 1996 2 1996 5
1996 9
45.5 kg,
110/70 mmHg, 80 / 36.5
가
3×3 cm
가
: 11.6 g/
dℓ
GOT/GPT 54/23 IU/L LDH 656
IU/L 가
CA 125 202 U/
Mℓ, CEA 1.47 ng/Mℓ, -FP 1.9 ng/Mℓ
estrogen 31.7 pg/Mℓ
: X-

Fig. 2. Granulosa cell tumor of the ovary showing diffuse pattern of growth. The tumor cells are ovoid or spindle-shaped and show occasional nuclear grooves and mitotic figures (H & E, ×200).

가
(Fig. 4).
: 1996 9

Fig. 4. Variable sized low density masses located in both hepatic lobes, perihepatic space and perisplenic space (abdominal CT).

가
nuclear groove
1/10 HPF
body (Fig. 5).
Call-Exner

Fig. 5. Metastatic granulosa cell tumor, Liver. Diffuse proliferation of spindle-shaped cells showing occasional mitotic figures (H & E, $\times 400$).

: 1996 9 16 paclitaxel 135 mg/m²,
carboplatin 400 mg/m²
, 1996 10 11 1996 10 19
2100 cGy
, 1996 10 28 etoposide 20 mg/m²,
cisplatin 20 mg/m²

1996 11 15 .
5
8%
.3 15%
2 3% .4 1983 7
1998 3 197 11 가
5.6%
1855 Rokitansky
, 50 60 . 가
5%
2%
75%
가
10%
.58 estrogen
가
가
가
25 50% 5%
.578
, 가 가
가
5 6% .2 Fox 2 10
74 22 22
가 .8
11 2
1 가 9.1%
. Margolin -

- References -

1. Norris, HJ, Taylor, HB. Prognosis of granulosa-theca cell tumors of the ovary, *Cancer* 1968;21:255-63.
2. Simmons RL, Sciarra JJ. Treatment of late recurrent granulosa cell tumor of the ovary. *Surg Gynecol Obstet* 1967;124:65-70.
3. Newlands ES, Southall PJ, Paradinas FJ, Holden L. Management of ovarian germ cell tumours. In: Williams CJ, Krikorian JG, Green MR, Ragavan D, editors. *Textbook of Uncommon Cancer*. New York: John Wiley & Sons Ltd 1988;p.37-53.
4. Malstrom H, Hogberg T, Risberg B, Simonsen E. Granulosa cell tumors of the ovary: prognostic factors and outcome, *Gynecol Oncol* 1994;52:50-5.
5. Young RH, Scully RE. Ovarian sex cord-stromal tumors: recent progress. *Int J Gynaecol Pathol* 1982;1:101-23.
6. Novak ER, Kutchmeshgi J, Mupas RS, Woodruff JD. Feminizing gonadal stromal tumors. *Obstet Gynecol* 1971;38:701-13.
7. Bjorkholm, Pettersson F. Granulosa-cell and theca-cell tumors. *Acta Obstet Gynecol Scand* 1980;59:361-5.
8. Fox H, Agrawal K, Langley FA. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. *Cancer* 1975;35:231-41.
9. Margolin KA, Pak HY, Esensten ML, Doroshow JH. Hepatic metastasis in granulosa cell tumor of the ovary. *Cancer* 1985;56:691-95.
10. Slayton RE, Johnson G, Brady L, Blessing J. Radiotherapy and chemotherapy in malignant tumors of the ovarian stroma: a Gynecologic Oncology Group study. *Proc Am Soc Clin Oncol* 1980;C444.
11. Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD et al: Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase trial of ip cisplatin and recombinant -interferon. *Gynecol Oncol* 1992;45:3-8.
12. Slayton RE. Management of germ cell and stromal tumors of the ovary. *Semin Oncol* 1984;11:299-313.